基于MultiTEP平台的靶向tau蛋白N端的DNA表位疫苗在THY-Tau22小鼠中诱导强免疫应答并减少tau病理
在THY-Tau22转基因小鼠3月龄起肌内注射靶向tau蛋白第2-18位氨基酸B细胞表位的AV-1980D DNA疫苗并电穿孔,诱导针对MultiTEP平台的特异性Th细胞激活和针对tau的强体液免疫,未检测到针对内源性tau的致病性自身反应性Th细胞激活。9月龄时疫苗显著降低脑提取物总tau及pS199、AT180磷酸化tau水平,对其他磷酸化tau种类影响轻微且无统计学意义。
要点
- AV-1980D电穿孔DNA疫苗在THY-Tau22小鼠中诱导针对tau的强抗体应答且无致病性自身反应性Th细胞激活。
- 抗tau抗体滴度在两次免疫后达最大值,随后五次每月免疫期间略低但保持稳定。
- 疫苗显著降低脑总tau及pS199、AT180磷酸化tau水平,对其他磷酸化tau种类影响无统计学意义。
核心结论
- 靶向tau蛋白N端的MultiTEP平台DNA表位疫苗在THY-Tau22小鼠模型中具有高免疫原性和治疗效力,电穿孔介导的DNA免疫是诱导高浓度抗tau抗体的有吸引力的替代方案。
研究设计与样本
- 在THY-Tau22转基因小鼠3月龄起肌内注射靶向tau蛋白第2-18位氨基酸B细胞表位的AV-1980D疫苗并电穿孔,9月龄时分析脑组织生化和免疫组化变化。
主要发现
- AV-1980D电穿孔疫苗接种诱导针对MultiTEP疫苗平台的特异性Th细胞激活和针对tau的强体液免疫应答。
- 未检测到针对内源性tau种类的潜在有害自身反应性Th细胞应答激活。
- 抗tau抗体最大滴度在两次免疫后达到,随后五次每月免疫期间保持略低但稳定。
- 疫苗接种显著降低脑提取物总tau及pS199和AT180磷酸化tau水平,但对其他磷酸化tau种类仅产生轻微非显著影响。
关键数值与推荐
- 疫苗靶向tau蛋白第2-18位氨基酸B细胞表位。
- 小鼠3月龄起始免疫,9月龄时进行神经病理分析。
- 共进行两次初始免疫及后续五次每月免疫。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: By the time clinical symptoms of Alzheimer's disease (AD) manifest in patients there is already substantial tau pathology in the brain. Recent evidence also suggests that tau pathology can become self-propagating, further accelerating disease progression. Over the last decade several groups have tested the efficacy of protein-based anti-tau immunotherapeutics in various animal models of tauopathy. Here we report on the immunological and therapeutic potency of the first anti-tau DNA vaccine based on the MultiTEP platform, AV-1980D, in THY-Tau22 transgenic mice. METHODS: Starting at 3months of age, mice were immunized intramuscularly with AV-1980D vaccine targeting a tau B cell epitope spanning aa2-18 followed by electroporation (EP). Humoral and cellular immune responses in vaccinated animals were analyzed by ELISA and ELISpot, respectively. Neuropathological changes in the brains of experimental and control mice were then analyzed by biochemical (WB and ELISA) and immunohistochemical (IHC) methods at 9months of age. RESULTS: EP-mediated AV-1980D vaccinations of THY-Tau22 mice induced activation of Th cells specific to the MultiTEP vaccine platform and triggered robust humoral immunity response specific to tau. Importantly, no activation of potentially harmful autoreactive Th cell responses specific to endogenous tau species was detected. The maximum titers of anti-tau antibodies were reached after two immunizations and remained slightly lower, but steady during five subsequent monthly immunizations. Vaccinations with AV-1980D followed by EP significantly reduced total tau and pS199 and AT180 phosphorylated tau levels in the brains extracts of vaccinated mice, but produced on subtle non-significant effects on other phosphorylated tau species. CONCLUSIONS: These data demonstrate that MultiTEP-based DNA epitope vaccination targeting the N-terminus of tau is highly immunogenic and therapeutically potent in the THY-Tau22 mouse model of tauopathy and indicate that EP-mediated DNA immunization is an attractive alternative to protein-based adjuvanted vaccines for inducing high concentrations of anti-tau antibodies.
引用
- Davtyan H, Chen WW, Zagorski K, et al. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine. 2017. PMID: 28320590. doi:10.1016/j.vaccine.2017.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。